← Eichor
Study identifier: NCT06692504 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Adverse Drug Events in Patients on Oral Anticoagulation in the Emergency Department

Condition: Hemorrhage · Thrombosis · Anticoagulant Therapy  ·  Sponsor: Centre Hospitalier Universitaire de Besancon

PhaseN/A
Planned participants2080
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

Rationale: According to the latest National Survey on Care-Related Adverse Events, anticoagulants, including vitamin K antagonists (VKAs), rank first among medications responsible for serious iatrogenic accidents (37% in 2004, 31% in 2009). The EMIR study (2007) showed that VKAs were the leading cause of hospitalization for adverse effects (12.3%), with approximately 5,000 fatal hemorrhage-related accidents annually. Treatment and prevention of thromboembolic events represent a major public health challenge due to increased mortality, severity of functional sequelae, growing number of patients requiring treatment, and medical, social, and economic consequences. In 2013, an estimated 3.12 million patients received anticoagulation (4-5% of the French population). Several types of adverse events under oral anticoagulation appear to have high incidence in emergency settings: traumatic hemorrhage, spontaneous hemorrhage, asymptomatic overdose, and thrombosis. Different variables are associated with these events in patients admitted to emergency departments under oral anticoagulant treatment, but few studies have been conducted in real-world settings with large patient samples. Hypothesis: Iatrogenic events have a high incidence in patients admitted to emergency departments under oral anticoagulants and are a factor in early and late morbidity and mortality. Primary Objective: To describe the characteristics of patients admitted to the emergency department on oral anticoagulan…

This description comes directly from the study's public registry record.

Talk to the study team

Omide TAHERI, MD, PhD  ·  03 81 66 70 28  ·  omide.taheri@gmail.com

Thibaut DESMETTRE, MD, PhD  ·  thibaut.desmettre@hug.ch

Always discuss trial participation with your own doctor first.

Locations (1)

CHU BesançonBesançon, FranceRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06692504